期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 76, 期 19, 页码 2267-2281出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.08.079
关键词
cancer; cardio-oncology; cardiotoxicity; training
资金
- Cancer Prevention Research Institute of Texas [RP18040]
- Children's Discovery Institute
- National Institutes of Health/National Cancer Institute [R01CA233601]
- Miami/Florida Heart Research Foundation
- Pfizer
- Novartis US
- Myocardial Solutions
- Longer Life Foundation
The innovative development of cancer therapies has led to an unprecedented improvement in survival outcomes and a wide array of treatment-related toxicities, including those that are cardiovascular in nature. Aging of the population further adds to the number of patients being treated for cancer, especially those with comorbidities. Such pre-existing and developing cardiovascular diseases pose some of the greatest risks of morbidity and mortality in patients with cancer. Addressing the complex cardiovascular needs of these patients has become increasingly important, resulting in an imperative for an intersecting discipline: cardio-oncology. Over the past decade, there has been a remarkable rise of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum of standard practice and training guidelines, although these are being actively pursued. In this council perspective document, the authors delineate the scope of practice in cardio-oncology and the proposed training requirements, as well as the necessary core competencies. This document also serves as a roadmap toward confirming cardio-oncology as a subspecialty in medicine. (C) 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据